Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: Influence of time between substrate and inducer administration

European Journal of Pharmaceutical Sciences

Volumn 56, Issue 1, 2014, Pages 1-15

  Baneyx, Guillaume ^a   Parrott, Neil ^a   Meille, Christophe ^a   Iliadis, Athanassios ^b   Lavé, Thierry ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Auto induction; Competitive inhibition; Drug drug interaction (DDI); Dynamic simulation; Physiologically based pharmacokinetic (PBPK) modeling; Study design recommendations

Indexed keywords

ALFENTANIL; CYTOCHROME P450 3A4; INTESTINE ENZYME; MIDAZOLAM; NIFEDIPINE; RIFAMPICIN; TRIAZOLAM; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; CYTOCHROME P450 3A INDUCER;

ACCURACY; ADJUSTMENT; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; PRIORITY JOURNAL; SIMULATION; BIOLOGICAL MODEL; BLOOD; CELL CULTURE; METABOLISM; TISSUE DISTRIBUTION;

ALFENTANIL; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INDUCERS; HEPATOCYTES; HUMANS; MIDAZOLAM; MODELS, BIOLOGICAL; NIFEDIPINE; RIFAMPIN; TISSUE DISTRIBUTION; TRIAZOLAM;

EID: 84895520896     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2014.02.002     Document Type: Article

References (85)

1. G. Acocella Clinical pharmacokinetics of rifampicin Clin. Pharmacokinet. 3 1978 108 127
2. G. Acocella, V. Pagani, M. Marchetti, G.C. Baroni, and F.B. Nicolis Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks Chemotherapy 16 1971 356 370
3. B. Agoram, W.S. Woltosz, and M.B. Bolger Predicting the impact of physiological and biochemical processes on oral drug bioavailability Adv. Drug Deliv. Rev. 50 Suppl. 1 2001 S41 67
4. L.M. Almond, J. Yang, M. Jamei, G.T. Tucker, and A. Rostami-Hodjegan Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction Curr. Drug Metab. 10 2009 420 432
5. R.P. Austin, P. Barton, S.L. Cockroft, M.C. Wenlock, and R.J. Riley The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties Drug Metab. Dispos. 30 2002 1497 1503
6. J.T. Backman, K.T. Olkkola, and P.J. Neuvonen Rifampin drastically reduces plasma concentrations and effects of oral midazolam Clin. Pharmacol. Ther. 59 1996 7 13
7. G. Baneyx, Y. Fukushima, and N. Parrott Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions Future Med. Chem. 4 2012 681 693
8. E. Chung, A.N. Nafziger, D.J. Kazierad, and J.S. Bertino Jr. Comparison of midazolam and simvastatin as cytochrome P450 3A probes Clin. Pharmacol. Ther. 79 2006 350 361
9. N. Doble, R. Shaw, C. Rowland-Hill, M. Lush, D.W. Warnock, and E.E. Keal Pharmacokinetic study of the interaction between rifampicin and ketoconazole J. Antimicrob. Chemother. 21 1988 633 635
10. H. Echizen, and M. Eichelbaum Clinical pharmacokinetics of verapamil, nifedipine and diltiazem Clin. Pharmacokinet. 11 1986 425 449
11. H.J. Einolf Comparison of different approaches to predict metabolic drug-drug interactions Xenobiotica 37 2007 1257 1294
12. EMA, 2010. Guideline on the Investigation of Drug Interactions. < http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/ 05/WC500090112.pdf >.
13. O.A. Fahmi, T.S. Maurer, M. Kish, E. Cardenas, S. Boldt, and D. Nettleton A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro Drug Metab. Dispos. 36 2008 1698 1708
14. FDA, 2006. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. < http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ ucm093664.htm#4 >.
15. FDA, 2012. Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. < http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM292362.pdf >.
16. M.F. Fromm, D. Busse, H.K. Kroemer, and M. Eichelbaum Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin Hepatology 24 1996 796 801
17. P.D. Garzone, and P.D. Kroboth Pharmacokinetics of the newer benzodiazepines Clin. Pharmacokinet. 16 1989 337 364
18. M. Gertz, J.D. Davis, A. Harrison, J.B. Houston, and A. Galetin Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations Curr. Drug Metab. 9 2008 785 795
19. M. Gertz, A. Harrison, J.B. Houston, and A. Galetin Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data Drug Metab. Dispos. 38 2010 1147 1158
20. H. Glaeser, S. Drescher, M. Eichelbaum, and M.F. Fromm Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes Br. J. Clin. Pharmacol. 59 2005 199 206
21. J.C. Gorski, S. Vannaprasaht, M.A. Hamman, W.T. Ambrosius, M.A. Bruce, B. Haehner-Daniels, and S.D. Hall The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity Clin. Pharmacol. Ther. 74 2003 275 287
22. D.J. Greenblatt, L.L. von Moltke, J.S. Harmatz, G. Chen, J.L. Weemhoff, C. Jen, C.J. Kelley, B.W. LeDuc, and M.A. Zinny Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice Clin. Pharmacol. Ther. 74 2003 121 129
23. F.P. Guengerich Cytochrome P450s and other enzymes in drug metabolism and toxicity AAPS J. 8 2006 E101 111
24. H. Guo, C. Liu, J. Li, M. Zhang, M. Hu, P. Xu, L. Liu, and X. Liu A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions J. Pharm. Sci. 102 2013 2819 2836
25. D. Hallifax, and J.B. Houston Evaluation of hepatic clearance prediction using in vitro data: emphasis on fraction unbound in plasma and drug ionisation using a database of 107 drugs J. Pharm. Sci. 101 2012 2645 2652
26. M.F. Hebert, R.M. Fisher, C.L. Marsh, D. Dressler, and I. Bekersky Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers J. Clin. Pharmacol. 39 1999 91 96
27. A.T. Heikkinen, G. Baneyx, A. Caruso, and N. Parrott Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus Eur. J. Pharm. Sci. 47 2012 375 386
28. N.J. Hewitt, E.L. Lecluyse, and S.S. Ferguson Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations Xenobiotica 37 2007 1196 1224
29. E. Iatsimirskaia, S. Tulebaev, E. Storozhuk, I. Utkin, D. Smith, N. Gerber, and T. Koudriakova Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents Clin. Pharmacol. Ther. 61 1997 554 562
30. M. Jamei, F. Bajot, S. Neuhoff, Z. Barter, J. Yang, A. Rostami-Hodjegan, and K. Rowland-Yeo A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine Clin. Pharmacokinet. 2013
31. C.A. Jamis-Dow, A.G. Katki, J.M. Collins, and R.W. Klecker Rifampin and rifabutin and their metabolism by human liver esterases Xenobiotica 27 1997 1015 1024
32. H.M. Jones, N. Parrott, K. Jorga, and T. Lave A novel strategy for physiologically based predictions of human pharmacokinetics Clin. Pharmacokinet. 45 2006 511 542
33. H.M. Judge, S.B. Patil, R.J. Buckland, J.A. Jakubowski, and R.F. Storey Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel J. Thromb. Haemost. 8 2010 1820 1827
34. L.I. Kajosaari, J. Laitila, P.J. Neuvonen, and J.T. Backman Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin Basic Clin. Pharmacol. Toxicol. 97 2005 249 256
35. M. Kato, K. Chiba, M. Horikawa, and Y. Sugiyama The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes Drug Metab. Pharmacokinet. 20 2005 236 243
36. E.D. Kharasch, A. Walker, C. Hoffer, and P. Sheffels Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis Clin. Pharmacol. Ther. 76 2004 452 466
37. J.C. Kolars, P. Schmiedlin-Ren, J.D. Schuetz, C. Fang, and P.B. Watkins Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes J Clin Invest 90 1992 1871 1878
38. M. Kozawa, M. Honma, and H. Suzuki Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with a reporter gene assay Drug Metab. Dispos. 37 2009 1234 1241
39. P.D. Kroboth, J.W. McAuley, F.J. Kroboth, R.J. Bertz, and R.B. Smith Triazolam pharmacokinetics after intravenous, oral, and sublingual administration J. Clin. Psychopharm. 15 1995 259 262
40. H.H. Kupferschmidt, H.R. Ha, W.H. Ziegler, P.J. Meier, and S. Krahenbuhl Interaction between grapefruit juice and midazolam in humans Clin. Pharmacol. Ther. 58 1995 20 28
41. C.J. la Porte, E.P. Colbers, R. Bertz, D.S. Voncken, K. Wikstrom, M.J. Boeree, P.P. Koopmans, Y.A. Hekster, and D.M. Burger Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers Antimicrob. Agents Chemother. 48 2004 1553 1560
42. J.E. Laine, S. Auriola, M. Pasanen, and R.O. Juvonen Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes Xenobiotica 39 2009 11 21
43. Y.Y. Lau, Y. Huang, L. Frassetto, and L.Z. Benet Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers Clin. Pharmacol. Ther. 81 2007 194 204
44. E. LeCluyse, A. Madan, G. Hamilton, K. Carroll, R. DeHaan, and A. Parkinson Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes J. Biochem. Mol. Toxicol. 14 2000 177 188
45. R.H. Levy, M.S. Dumain, and J.L. Cook Time-dependent kinetics. V: Time course of drug levels during enzyme induction (one-compartment model) J. Pharmacokinet. Biopharm. 7 1979 557 578
46. J.J. Lilja, K.T. Kivisto, J.T. Backman, and P.J. Neuvonen Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life Eur. J. Clin. Pharmacol. 56 2000 411 415
47. J.H. Lin Challenges in drug discovery: lead optimization and prediction of human pharmacokinetics Pharmaceutical Profiling in Drug Discovery for Lead Selection 2004 AAPS Press Arlington, VA 293 325
48. J.H. Lin CYP induction-mediated drug interactions: in vitro assessment and clinical implications Pharm. Res. 23 2006 1089 1116
49. U. Loos, E. Musch, J.C. Jensen, G. Mikus, H.K. Schwabe, and M. Eichelbaum Pharmacokinetics of oral and intravenous rifampicin during chronic administration Klin. Wochenschr 63 1985 1205 1211
50. A.T. Lu, M.E. Frisella, and K.C. Johnson Dissolution modeling: factors affecting the dissolution rates of polydisperse powders Pharm. Res. 10 1993 1308 1314
51. Lukacova, V., Parrott, N., Lave, T., Fraczkiewicz, G., Bolger, M.B., Woltosz, W.S., 2008. General Approach to Calculation of Tissue: Plasma Partition Coefficients for Physiologically Based Pharmacokinetic (PBPK) Modeling. AAPS Annual Meeting and Exposition, Atlanta 2008, Poster, November 16-20.
52. M.A. Lyons, B. Reisfeld, R.S. Yang, and A.J. Lenaerts A physiologically based pharmacokinetic model of rifampin in mice Antimicrob. Agents Chemother. 57 2013 1763 1771
53. M.O. Magnusson, M.L. Dahl, J. Cederberg, M.O. Karlsson, and R. Sandstrom Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin Clin. Pharmacol. Ther. 84 2008 52 62
54. W. McCloskey, K. Zaiken, and R. Couris Clinically significant grapefruit juice-drug interactions Nutr. Today 43 2008 19 26
55. A. McLachlan, and I. Ramzan Meals and medicines Aust. Prescriber 29 2006 40 42
56. M. Niemi, J.T. Backman, M.F. Fromm, P.J. Neuvonen, and K.T. Kivisto Pharmacokinetic interactions with rifampicin: clinical relevance Clin. Pharmacokinet. 42 2003 819 850
57. M.F. Paine, D.D. Shen, K.L. Kunze, J.D. Perkins, C.L. Marsh, J.P. McVicar, D.M. Barr, B.S. Gillies, and K.E. Thummel First-pass metabolism of midazolam by the human intestine Clin. Pharmacol. Ther. 60 1996 14 24
58. M.F. Paine, M. Khalighi, J.M. Fisher, D.D. Shen, K.L. Kunze, C.L. Marsh, J.D. Perkins, and K.E. Thummel Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism J. Pharmacol. Exp. Ther. 283 1997 1552 1562
59. N. Parrott, and T. Lave Applications of physiologically based absorption models in drug discovery and development Mol. Pharm. 5 2008 760 775
60. C.A. Peloquin, G.S. Jaresko, C.L. Yong, A.C. Keung, A.E. Bulpitt, and R.W. Jelliffe Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide Antimicrob. Agents Chemother. 41 1997 2670 2679
61. S.A. Peters Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis Clin. Pharmacokinet. 47 2008 261 275
62. A. Poirier, C. Funk, J.M. Scherrmann, and T. Lave Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine Mol. Pharm. 6 2009 1716 1733
63. P. Poulin, C.E. Hop, Q. Ho, J.S. Halladay, S. Haddad, and J.R. Kenny Comparative assessment of in vitro-in vivo extrapolation methods used for predicting hepatic metabolic clearance of drugs J. Pharm. Sci. 101 2012 4308 4326
64. P. Poulin, J.R. Kenny, C.E. Hop, and S. Haddad In vitro-in vivo extrapolation of clearance: modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods J. Pharm. Sci. 101 2012 838 851
65. T.J. Rashid, U. Martin, H. Clarke, D.G. Waller, A.G. Renwick, and C.F. George Factors affecting the absolute bioavailability of nifedipine Br. J. Clin. Pharmacol. 40 1995 51 58
66. M.L. Reitman, X. Chu, X. Cai, J. Yabut, R. Venkatasubramanian, S. Zajic, J.A. Stone, Y. Ding, R. Witter, C. Gibson, K. Roupe, R. Evers, J.A. Wagner, and A. Stoch Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design Clin. Pharmacol. Ther. 89 2011 234 242
67. S.L. Ripp, J.B. Mills, O.A. Fahmi, K.A. Trevena, J.L. Liras, T.S. Maurer, and S.M. de Morais Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction Drug Metab. Dispos. 34 2006 1742 1748
68. T. Rodgers, and M. Rowland Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions J. Pharm. Sci. 95 2006 1238 1257
69. T. Rodgers, D. Leahy, and M. Rowland Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases J. Pharm. Sci. 94 2005 1259 1276
70. A. Rostami-Hodjegan, and G.T. Tucker Simulation and prediction of in vivo drug metabolism in human populations from in vitro data Nat. Rev. Drug Discov. 6 2007 140 148
71. J. Sahi, G. Hamilton, M. Sinz, S. Barros, S.M. Huang, L.J. Lesko, and E.L. LeCluyse Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes Xenobiotica 30 2000 273 284
72. J. Scholz, M. Steinfath, and M. Schulz Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update Clin. Pharmacokinet. 31 1996 275 292
73. M. Shou, M. Hayashi, Y. Pan, Y. Xu, K. Morrissey, L. Xu, and G.L. Skiles Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction Drug Metab. Dispos. 36 2008 2355 2370
74. Simulations Plus Inc. < http://www.simulations-plus.com/ >.
75. D.A. Smith Induction and drug development Eur. J. Pharm. Sci. 11 2000 185 189
76. H. Takanaga, A. Ohnishi, H. Matsuo, H. Murakami, H. Sata, K. Kuroda, A. Urae, S. Higuchi, and Y. Sawada Pharmacokinetic analysis of felodipine- grapefruit juice interaction based on an irreversible enzyme inhibition model Br. J. Clin. Pharmacol. 49 2000 49 58
77. I. Tamai Oral drug delivery utilizing intestinal OATP transporters Adv. Drug Deliv. Rev. 64 2012 508 514
78. T. Tateishi, M. Watanabe, H. Nakura, M. Asoh, H. Shirai, Y. Mizorogi, S. Kobayashi, K.E. Thummel, and G.R. Wilkinson CYP3A activity in European American and Japanese men using midazolam as an in vivo probe Clin. Pharmacol. Ther. 69 2001 333 339
79. I.E. Templeton, J.B. Houston, and A. Galetin Predictive utility of in vitro rifampin induction data generated in fresh and cryopreserved human hepatocytes, Fa2N-4, and HepaRG cells Drug Metab. Dispos. 39 2011 1921 1929
80. R.G. Tirona, B.F. Leake, A.W. Wolkoff, and R.B. Kim Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation J. Pharmacol. Exp. Ther. 304 2003 223 228
81. S.R. Vavricka, J. Van Montfoort, H.R. Ha, P.J. Meier, and K. Fattinger Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver Hepatology 36 2002 164 172
82. Y. Xu, Y. Zhou, M. Hayashi, M. Shou, and G.L. Skiles Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs Drug Metab. Dispos. 39 2011 1139 1148
83. J. Yang, M. Jamei, K.R. Yeo, G.T. Tucker, and A. Rostami-Hodjegan Prediction of intestinal first-pass drug metabolism Curr. Drug Metab. 8 2007 676 684
84. J. Yang, M. Liao, M. Shou, M. Jamei, K.R. Yeo, G.T. Tucker, and A. Rostami-Hodjegan Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions Curr. Drug Metab. 9 2008 384 394
85. P. Zhao, L. Zhang, J.A. Grillo, Q. Liu, J.M. Bullock, Y.J. Moon, P. Song, S.S. Brar, R. Madabushi, T.C. Wu, B.P. Booth, N.A. Rahman, K.S. Reynolds, E. Gil Berglund, L.J. Lesko, and S.M. Huang Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review Clin. Pharmacol. Ther. 89 2011 259 267